Background. Perioperative blood transfusion in pancreatic cancer patients is linked to decreased survival; however, a causal mechanism has not been determined. Previously we have shown that the plasma fraction of stored packed red blood cells (pRBCs) promotes pancreas cancer progression and associated morbidity. We hypothesize these untoward effects will be mitigated by use of a hemoglobin-based oxygen carrier (HBOC). Methods. Cytokines and growth factors were measured in the plasma fraction from stored pRBCs and in an HBOC via cytokine array followed by formal enzyme-linked immunosorbent assay (ELISA). In an immunocompetent murine model, pancreas cancer progression was determined in vivo by bioluminescence, tumor weight, and number of metastases. Results. Elevated levels of epidermal growth factor (EGF), platelet-derived growth factor BB (PDGF-BB), and regulated upon activation, normal T cell expressed and secreted (RANTES) were present in the plasma fraction of stored pRBCs, but were not found in the HBOC. Intravenous delivery of plasma fraction to mice with pancreatic cancer resulted in increased bioluminescence activity compared with mice that received HBOC. Metastatic events and pancreatic primary tumor weights were significantly higher in animals receiving plasma fraction from stored pRBCs compared with animals receiving HBOC. Conclusions. Intravenous receipt of the acellular plasma fraction of stored pRBCs promotes pancreatic cancer progression in an immunocompetent mouse model. These untoward events are mitigated by use of an HBOC.
ABSTRACT
Background. Perioperative blood transfusion in pancreatic cancer patients is linked to decreased survival; however, a causal mechanism has not been determined. Previously we have shown that the plasma fraction of stored packed red blood cells (pRBCs) promotes pancreas cancer progression and associated morbidity. We hypothesize these untoward effects will be mitigated by use of a hemoglobin-based oxygen carrier (HBOC). Methods. Cytokines and growth factors were measured in the plasma fraction from stored pRBCs and in an HBOC via cytokine array followed by formal enzyme-linked immunosorbent assay (ELISA). In an immunocompetent murine model, pancreas cancer progression was determined in vivo by bioluminescence, tumor weight, and number of metastases. Results. Elevated levels of epidermal growth factor (EGF), platelet-derived growth factor BB (PDGF-BB), and regulated upon activation, normal T cell expressed and secreted (RANTES) were present in the plasma fraction of stored pRBCs, but were not found in the HBOC. Intravenous delivery of plasma fraction to mice with pancreatic cancer resulted in increased bioluminescence activity compared with mice that received HBOC. Metastatic events and pancreatic primary tumor weights were significantly higher in animals receiving plasma fraction from stored pRBCs compared with animals receiving HBOC. Conclusions. Intravenous receipt of the acellular plasma fraction of stored pRBCs promotes pancreatic cancer progression in an immunocompetent mouse model. These untoward events are mitigated by use of an HBOC.
Perioperative transfusion of stored packed red blood cells (pRBCs) is potentially a lifesaving measure. Approximately 5 million patients in the USA receive blood transfusions annually. 1 Unfortunately, allogeneic blood transfusion is not without risks, including transfusion reactions, bacterial and viral infections, and effects on the recipient's immune system, which although uncertain in etiology is well known as transfusion-related immunomodulation (TRIM). TRIM was first described by Opelz in the 1970s after renal transplant allografts were noted to survive longer in patients who had preoperative blood transfusions. 2 The immunosuppressive effect of allogeneic blood transfusion was of such benefit that renal transplant patients were routinely transfused with pRBCs while awaiting transplantation.
Not long after the seminal work of Opelz et al. demonstrating increased renal allograft survival, Gantt 3 hypothesized that the immunosuppressive effect of allogeneic blood transfusion would promote increased cancer growth and metastasis. More recently, two large clinical studies have shown that blood transfusion negatively impacts survival in patients with periampullary (pancreas) cancer. 4, 5 Although these retrospective reviews are compelling, it is difficult to determine whether the need for transfusion in the perioperative setting is a surrogate for tumor size and biologic activity, or if the transfusion in and of itself represents a causative factor in patient demise. Recent use of an in vivo model of murine pancreatic cancer has allowed us to control for many perioperative variables, including individual genetic factors, tumor inoculums, and surgical trauma. This model demonstrated that receipt of the fraction of plasma from pRBCs augmented pancreas cancer growth as well as weight loss and ascites. 6 As blood transfusion during pancreas surgery is often unavoidable, with transfusion rates as high as 75 %, we hypothesized that use of a hemoglobin-based oxygen carrier (HBOC) to correct deficits of volume and oxygen delivery would mitigate untoward effects of pRBC transfusion related to pancreas cancer progression. 4, 5, 7 
METHODS

Plasma Preparation from Stored pRBCs
After obtaining informed consent under a protocol approved by the Colorado Multi-Institutional Review Board, ten healthy donors donated 450 ml of whole blood per American Association of Blood Banks (AABB) criteria as described. 8 Samples from these pRBC units, both prestorage leukoreduced units (LR) and nonleukoreduced units (NLR) on day 1 and day 42, were obtained via sterile couplers, and the plasma was separated by centrifugation. 8 Following plasma isolation, a second spin (12,5009g for 5 min) was performed to remove acellular debris. 9 Plasma was aliquoted and stored at -80°C. An HBOC (Polyheme Ò ) was obtained from Northfield Laboratories Inc. (Evanston IL) and stored at 4°C per the manufacturer's instructions.
Measurement of Cytokines and Chemokines
The cytokines in the HBOC as well as plasma from LR and NLR pRBCs at day 1 and day 42 of storage were measured using a commercially available cytokine kit (Chemicon These data were then used to select pro-oncogenic cytokines that our laboratory group had experience working with in murine models, particularly with the use of blocking antibodies. We performed further analysis via commercial ELISA for specific cytokines. Commercially available kits from R&D Systems, Inc. (Minneapolis, MN) for epidermal growth factor (EGF), platelet-derived growth factor BB (PDGF-BB), and regulated upon activation, normal T cell expressed and secreted (RANTES, CCL5) were used according to the manufacturer's recommendations.
Orthotopic Immunocompetent Murine Model of Pancreatic Cancer
All murine studies were carried out according to the guidelines of the American Association for Accreditation of Laboratory Care and The University of Texas Southwestern Animal Care and Use Committee. Pan02 cells, a murine pancreatic cancer cell line, were obtained from the National Cancer Institute, Frederick, MD. Pan02 cells transfected with luciferase (''Pan02-luc,'' a generous gift of Dr. Jerry Shay, UT Southwestern) were given via orthotopic injection (2.5 9 10 5 cells) as described. 10 Mice were randomized 1 week post tumor injection to receive lateral tail vein (LTV) injection of either saline, HBOC, or the plasma fraction from pRBCs at day 1 or day 42 of storage. Volume was calculated at 1 cc/kg, which is equivalent to the volume of plasma received in a 2-unit pRBC transfusion. The plasma fraction was obtained from NLR pRBCs. Bioluminescence imaging (BLI) was determined as described using an IVIS machine with photon flux/second measured. Animals were clinically followed, weighed two times per week, and sacrificed 6 weeks after the orthotopic injection of tumor cells. 11, 12 A second set of experiments was performed using nonluciferase-transfected Pan02 cells to determine primary tumor progression and metastasis at necropsy.
In the second experiment, mice received 500,000 nontransfected Pan02 cells via splenic injection as described. 10, 13 One week postprocedure, animals were randomized to receive LTV injection of saline, acellular plasma fraction of day 42 NLR pRBCs in either a 2U or a 6U transfusion volume, or the equivalent volume of HBOC. Animals were clinically followed, weighed two times per week, and sacrificed 4 weeks after the splenic injection of tumor cells. 12 Blinded necropsy was performed, and extent of disease was quantified, noting tumor size, visible metastatic disease, and tumor sequelae. At the time of necropsy, liver, lymph node, and peritoneal metastases were identified by blinded investigators via visual inspection to confirm numbers of metastases and weight of metastatic foci (data not shown); N C 5 in all groups.
Statistical Analysis
Data are expressed as mean ± standard error of the mean. One-way analysis of variance (ANOVA) testing was performed to determine the significance of observed differences. Fisher's protected least significant difference (PLSD) was performed for post hoc comparisons. Statistical significance was determined at p \ 0.05.
RESULTS
Measurement of Cytokines
Cytokine Antibody Array was performed on both NLR and LR plasma fraction of pRBCs stored for day 1 and day 42, as well as on polymerized hemoglobin. In the plasma fraction of pRBCs, the Chemiarray identified elevated levels of multiple pro-oncogenic cytokines. EGF, RANTES (CCL-5), and PDGF-BB are known to be prooncogenic cytokines that were present in both the NLR and the LR plasma fraction of pRBCs. Further ELISA testing was then performed, revealing significant levels of PDGF-BB and EGF in the NLR plasma fraction from day 42 of storage. No cytokines were detected in HBOC (Fig. 1) .
Determination of Orthotopic Pancreas Cancer Progression by Bioluminescence
Tumor bioluminescence was determined weekly, status post LTV injection until 6 weeks after tumor injection. Use of luciferase-transfected Pan02 cells allowed noninvasive determination of pancreas tumor progression, as shown in Fig. 2 (representative image) , where IVIS demonstrates tumor bioluminescence. Mice that received LTV injection of 2 unit equivalents of 42-day-old NLR pRBCs (mouse C) had the most bioluminescence activity when compared with mice that received HBOC (B) and mice that received normal saline (A).
Determination of Metastatic Events and Primary Pancreas Disease
Animals receiving NLR plasma fraction from day 42 pRBCs at both the 2U and 6U transfusion dose had larger primary tumors and more metastatic events than did either the saline control group or the 6U HBOC group (Table 1) . There was a significant increase in the number of metastatic lesions in mice that received a 2-unit equivalent of plasma fraction of pRBCs over mice that received saline. Mice that received a 2 unit volume of HBOC had less metastatic lesions than mice that received 2 units of pRBCs with a p value approaching significance at p = 0.06. However, the difference in metastatic lesions is clearly demonstrated in comparing mice that received the higherdose transfusion. Mice that received the 6-unit equivalent of pRBCs had on average 2.7 metastases, while the mice that received saline and the mice that received the 6-unit equivalent of HBOC both had no metastases. Furthermore, the weight of the primary tumor was also significantly higher in mice that received the plasma fraction of pRBCs when compared with the mice that received normal saline or the equivalent volume of HBOC.
DISCUSSION
Although large clinical series suggest a negative impact of blood transfusion on postoperative pancreas cancer survival, a clear causal relationship between transfusion and poor survival is difficult to establish. 4, 5 Recent preclinical work using an immunocompetent animal model suggests that transfusion of the plasma fraction of pRBCs significantly augments pancreas cancer growth and metastasis, wherein genetic differences, tumor volume, and surgical stress are able to be more tightly controlled. 6 Interestingly, using this model, transfusion of the plasma fraction of pRBCs from day 1 and day 42 of storage did not lead to a statistical difference in tumor progression, suggesting that factors present upon the storage of pRBCs may be responsible for the observed effects on tumor growth. It should be noted, however, that storage time did increase morbidity in terms of ascites, hair loss, and inability of animals to maintain weight. 6 Importantly, the apparent lack of procancer cytokines within the HBOC suggests that it may be safer in the acute setting for maintaining homeostasis of volume and oxygen delivery without the untoward effects of stored pRBCs.
The use of HBOC has been studied in trauma as an alternative to blood for resuscitation. While transfusion of stored packed red blood cells (pRBCs) may be a lifesaving measure, pRBCs contain biologic mediators that have been implicated in the exacerbation of early postinjury hyperinflammation and multiple organ failure. This is thought to 14 Further, using trauma models, it has been suggested that use of HBOC avoids PMN priming, thus decreasing multiple organ failure. [15] [16] [17] There are several limitations of this study that warrant discussion: (1) Plasma contains many substances that could affect the host response, and the effect of individual agents is difficult to determine. We have specifically screened for 42 cytokines and specifically tested those known to be prooncogenic, for which our laboratory has experience working with in a murine model. This group of cytokines is not comprehensive, but a starting point for further investigations. (2) Human plasma was used in this model, and the mouse immune response to potential foreign proteins is difficult to predict. However, the HBOC is also derived from human hemoglobin and should partially control for some of the observed effects. Using blood from a syngeneic source would be ideal, but is logistically difficult considering the need for similar harvesting, processing, and storage techniques to make the model clinically relevant. Multiple studies by Silliman et al. [18] [19] [20] have demonstrated acute lung injury after transfusion of plasma from stored but not fresh pRBCs that is reproducible using multiple blood donors with no idiosyncratic effects noted in those studies. (3) Many of the parameters used to determine disease severity, such as identification of cancerous lesions (lymph node, liver, peritoneal metastases) as well as jaundice and visceral obstruction, are subjective. Two blinded observers were employed for confirmation of findings at necropsy to avert bias. Despite these issues, this model has clinical relevance and warrants further confirmation with more sophisticated studies in the future.
Blood products are given intravenously to cancer patients in the perioperative period every day, and the effects on cancer-related morbidity and death have yet to be proven. This study attempted to control for many of the variables present in the clinical setting. In summary, these data suggest that bioactive substances capable of affecting the tumor biology within an organism are present within 24 h of storage of erythrocytes. The substances and mechanism of action remain to be elucidated; however, these studies offer an avenue for investigation and identification of strategies for intervention.
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